Brief: Antengene Corp Says Xpovio Approved In China For Second-Line Multiple Myeloma Treatment
28/07/2025 11:25
July 28 (Reuters) - Antengene Corp Ltd 6996.HK: XPOVIO APPROVED IN CHINA FOR SECOND-LINE MULTIPLE MYELOMA TREATMENT Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106